Adrian Sidelko

Not financial advice. Do your own research (DYOR)

[Adrian Sidelko @AdrianRoba83038]

#OCGN #Ocugen #GeneTherapy #ASRS2026

[Adrian Sidelko @AdrianRoba83038]

If you enjoy my biotech research and #OCGN updates, feel free to follow me 🙂

[Adrian Sidelko @AdrianRoba83038]

#OCGN #Ocugen #GeneTherapy #Biotech

[Adrian Sidelko @AdrianRoba83038]

Who's still holding $OCGN? 👀
Big pullback after the recent run.
Still holding strong or did today's volatility shake you out?
💎 Holding 😬 Sold
#OCGN #Biotech #Stocks #NASDAQ #SmallCaps #Trading #Investing

[Adrian Sidelko @AdrianRoba83038]

Healthy pullbacks are part of every strong trend.
After a +20% move, profit-taking is completely normal.
The key isn't today's red candle — it's whether the stock holds key support and whether buyers step back in.
Stay patient. 📈
#OCGN #Ocugen #Biotech #NASDAQ #Momentum

[Ocugen @Ocugen]

Understanding the retina is an important step in vision health. Many #retinaldiseases are linked to genetic mutations that can lead to vision loss. #Ocugen is advancing modifier gene therapies designed to address the causes of these rare conditions and help preserve vision.

[Adrian Sidelko @AdrianRoba83038]

🚀 2 HOURS AFTER THE MARKET OPEN
$OCGN is holding strong above $1.60 with impressive momentum.
✅ Strong buying pressure
✅ Breakout holding
✅ Volume remains elevated
The market is starting to pay attention.
Is this just the beginning? 👀💥
#OCGN #Ocugen #Biotech #Stocks #NASDAQ

[Adrian Sidelko @AdrianRoba83038]

If volume continues to build above today's level, this breakout becomes much more credible.

Volume tells the truth.

#OCGN #Ocugen

[Adrian Sidelko @AdrianRoba83038]

What's your move? Let me know in the comments! 👇
#OCGN #Ocugen #Biotech #BiotechStocks #NASDAQ #StockMarket #Stocks #Investing #Investor #Trading #SwingTrading #Momentum #ShortSqueeze #Bullish #GrowthStocks #Pharma #GeneTherapy #StockTwits #FinTwit #DYOR

[Adrian Sidelko @AdrianRoba83038]

Bulls continue defending the $1.40 area while the pipeline remains packed with potential catalysts:
🧬 OCU400 rolling BLA
👁️ OCU410ST interim data
👁️ OCU410 Phase 3 progress
🤝 Partnership potential
Strong volume today?
#OCGN #Biotech #GeneTherapy #NASDAQ #Investing #Stocks #DYOR

[Ocugen @Ocugen]

Connie Collingsworth, Member of our Business Advisory Board and former COO of the @gatesfoundation, met with CEO @drsmusunuri this week to discuss global access partnerships as we work to advance transformative modifier gene therapies for patients around the world. #GlobalHealth

[Adrian Sidelko @AdrianRoba83038]

@ChicagoMuniPro_ David, if you have something constructive to add, I'm happy to discuss. Otherwise, please stop spamming my posts. Thanks.

[Adrian Sidelko @AdrianRoba83038]

$OCGN
My prediction:
📍Healthy consolidation 📍Higher low 📍Reclaim $1.40 📍$1.45 next
I'm more interested in the structure than the hourly noise.
As long as $1.30 holds, the breakout thesis is alive.
Patience pays. 👀🚀
#OCGN #Biotech #Momentum #Stocks #ocugen

[Adrian Sidelko @AdrianRoba83038]

@ChicagoMuniPro_ @BenScottStevens Bot

[Adrian Sidelko @AdrianRoba83038]

@ChicagoMuniPro_ @spoonlocks Bot

[Adrian Sidelko @AdrianRoba83038]

@ChicagoMuniPro_ @clipfullyloaded Bot

[Adrian Sidelko @AdrianRoba83038]

@ChicagoMuniPro_ @JamCristopher Bot

[Adrian Sidelko @AdrianRoba83038]

OCGN is building one of the most interesting retina gene therapy pipelines.
Upcoming catalysts: 👁️ OCU400 (RP) 🧬 OCU410ST (Stargardt) 🔬 OCU410
Not financial advice. DYOR.
#OCGN #Ocugen #Biotech #GeneTherapy #Retina #RetinitisPigmentosa #Stargardt #Investing #Stocks #SmallCaps

[Adrian Sidelko @AdrianRoba83038]

@Hap0606 At the moment I can't really help with specific picks. I'm still building my own positions and doing my research. But if I find new opportunities worth sharing, you'll definitely hear about them over time. 👊📈

[Adrian Sidelko @AdrianRoba83038]

$OCGN
$1.30 was called "strong resistance."
Now it's acting like support.
✅ Higher highs
✅ Higher lows
✅ Every dip gets bought
✅ BIO week
✅ Partnership discussions
✅ Q3 catalysts ahead
Shorts had plenty of time.
Now the pressure is on them.
Patience pays. 👀🚀
#OCGN #Ocugen

[Adrian Sidelko @AdrianRoba83038]

@Hap0606 OCGN is still proving itself. I'd rather wait for confirmation than guess the next move. I look for companies with strong long-term potential and asymmetric risk/reward.